Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gerber

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Expert Opinion on Investigational Drugs|December 4, 2003
Angiogenesis: new opportunities and solutions for drug development. Predictive markers for antiangiogenic drugsHans-Peter Gerber
Drug Discovery Today|April 12, 2003
Anti-angiogenesis: biology is the foundation for therapyHans Peter Gerber
Biochemical Pharmacology|January 26, 2010
Emerging immunotherapies targeting CD30 in Hodgkin's lymphomaHans-Peter Gerber
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 15, 2015
Subungual malignant melanomaStephan Braun, Peter Gerber
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|March 13, 2018
Response to Paired EditorialAnders Thorell, Peter Gerber
Cancer Research|February 12, 2005
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesHans-Peter Gerber, Napoleone Ferrara
Journal of Molecular Medicine (Berlin, Germany)|January 25, 2003
The role of VEGF in normal and neoplastic hematopoiesisHans-Peter Gerber, Napoleone Ferrara
ACS Medicinal Chemistry Letters|November 25, 2016
Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer TherapyJagath Reddy Junutula, Hans-Peter Gerber
Frontiers in Oncology|November 7, 2022
TCR mimic compounds for pHLA targeting with high potency modalities in oncologyHans-Peter Gerber, Leonard G Presta
Nature Medicine|June 5, 2003
The biology of VEGF and its receptorsNapoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Expert Opinion on Investigational Drugs|December 4, 2003
Angiogenesis: new opportunities and solutions for drug development. Predictive markers for antiangiogenic drugsHans-Peter Gerber
Drug Discovery Today|April 12, 2003
Anti-angiogenesis: biology is the foundation for therapyHans Peter Gerber
Biochemical Pharmacology|January 26, 2010
Emerging immunotherapies targeting CD30 in Hodgkin's lymphomaHans-Peter Gerber
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 15, 2015
Subungual malignant melanomaStephan Braun, Peter Gerber
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|March 13, 2018
Response to Paired EditorialAnders Thorell, Peter Gerber
Cancer Research|February 12, 2005
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesHans-Peter Gerber, Napoleone Ferrara
Journal of Molecular Medicine (Berlin, Germany)|January 25, 2003
The role of VEGF in normal and neoplastic hematopoiesisHans-Peter Gerber, Napoleone Ferrara
ACS Medicinal Chemistry Letters|November 25, 2016
Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer TherapyJagath Reddy Junutula, Hans-Peter Gerber
Frontiers in Oncology|November 7, 2022
TCR mimic compounds for pHLA targeting with high potency modalities in oncologyHans-Peter Gerber, Leonard G Presta
Nature Medicine|June 5, 2003
The biology of VEGF and its receptorsNapoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter
Pageof 11